Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme
This opens up a huge market for the company’s Magnezis implants in India
The company plans to expand its portfolio in regulated markets aggressively
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
The consideration for the medicines in India is valued at Rs 180.48 crore
The state-of-the-art facility provides a pathway from development to large-scale biologics production
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
Global Health operates a network of four hospitals under the Medanta brand in Gurugram, Indore, Ranchi and Lucknow. In addition, one hospital is under construction in Patna, and another is planned for development in Noida
The acquisition complements and strengthens Merck’s cardiovascular pipeline
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
Its DirectDetect reagent eliminates RNA extraction for rapid deployment of Covid-19 tests in affected countries
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
It is a recombinant nanoparticle protein-based vaccine
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
The company is the Clinical Research Organisation of Caplin Point Laboratories
Subscribe To Our Newsletter & Stay Updated
